US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
VanEck Pharmaceutical ETF
(NQ:
PPH
)
114.63
-0.16 (-0.14%)
Official Closing Price
Updated: 4:15 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about VanEck Pharmaceutical ETF
< Previous
1
2
3
Next >
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
↗
October 26, 2026
IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: Simplify’s Active PINK or VanEck’s Pharma-Focused PPH?
↗
October 11, 2026
VanEck offers lower costs and higher dividends with a concentrated pharma focus, while Simplify provides broader healthcare exposure and donates profits to breast cancer research.
Via
The Motley Fool
Topics
ETFs
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
↗
October 02, 2026
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Via
The Motley Fool
Topics
ETFs
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report
↗
February 12, 2026
Via
Stocktwits
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits?
↗
September 15, 2026
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.
Via
The Motley Fool
Topics
ETFs
Should You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs. Invesco Healthcare ETF Compared.
↗
September 11, 2026
PPH offers concentrated pharma exposure with 1.9% yield and lower volatility, while RSPH provides broader diversification across 60 healthcare holdings.
Via
The Motley Fool
Topics
ETFs
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
↗
August 26, 2026
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
Via
The Motley Fool
Topics
ETFs
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?
↗
August 18, 2026
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.
Via
The Motley Fool
Topics
ETFs
PPH vs. IYH: Which Healthcare Fund Is the Better Buy?
↗
August 18, 2026
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
Via
The Motley Fool
Topics
ETFs
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?
↗
August 12, 2026
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.
Via
The Motley Fool
Topics
ETFs
Is the VanEck Pharmaceutical ETF or State Street Health Care ETF the Better Buy for Your Portfolio?
↗
July 26, 2026
PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee.
Via
The Motley Fool
Topics
ETFs
Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ
↗
July 23, 2026
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The...
Via
The Motley Fool
Topics
ETFs
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
↗
July 20, 2026
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Via
The Motley Fool
Topics
ETFs
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
↗
July 09, 2026
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
Via
The Motley Fool
Topics
ETFs
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
↗
July 04, 2026
Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.
Via
The Motley Fool
Topics
ETFs
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy?
↗
June 18, 2026
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals.
Via
The Motley Fool
Topics
ETFs
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns.
↗
June 02, 2026
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
Via
The Motley Fool
Topics
ETFs
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem
↗
May 27, 2026
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles.
Via
The Motley Fool
Topics
ETFs
Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock
↗
March 10, 2026
BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy
↗
March 09, 2026
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
FDA Vaccine Chief Vinay Prasad To Exit Agency In April: Report
↗
March 06, 2026
The Wall Street Journal reported the upcoming departure on Friday, citing FDA Commissioner Marty Makary.
Via
Stocktwits
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes
↗
February 25, 2026
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.
Via
Stocktwits
Why Did GERN Stock Tumble 10% Pre-Market Today?
↗
February 25, 2026
Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.
Via
Stocktwits
Topics
Artificial Intelligence
Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report
↗
February 24, 2026
According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.
Via
Stocktwits
Topics
Artificial Intelligence
NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China
↗
February 24, 2026
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.
Via
Stocktwits
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry
↗
February 23, 2026
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.
Via
Stocktwits
Topics
Intellectual Property
Why Is NVO Stock Falling Pre-Market Today?
↗
February 23, 2026
The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.
Via
Stocktwits
Topics
Government
FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains
↗
February 09, 2026
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.
Via
Stocktwits
Topics
Lawsuit
Why Did IINN Stock Surge 28% In Pre-Market Today?
↗
February 09, 2026
The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.
Via
Stocktwits
Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks
↗
February 09, 2026
Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.
Via
Stocktwits
Topics
Intellectual Property
Lawsuit
< Previous
1
2
3
Next >
